Anti Cancer Medicines

This molecule is marketed by Incepta with brand name Osicent 80 mg Tablet.It is prescribed to Lung cancer patients.

Abiraterone 500 mg

Cabozanib (Cabozanitinib) anti cancer medicine

Anti Cancer Medicine

Anti cancer Medicines

Crizonix (Crizotinib) anti cancer medicine

palbocent (palbociclib) 125 mg anti cancer medicines

Afanix (Afatinib) anti cancer Medicines

capegard (capecitabine) Anti cancer tablets

ENZALUTAMIDE 40mg Capsule is used in the treatment of cancer of the prostate gland. It may be also used to treat other conditions, as determined by the doctor. It works by blocking the effects of male hormones such as testosterone.ENZALUTAMIDE 40mg Capsule should be taken with or without food, preferably at a fixed time every day. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

“Mylan Inc. has received a tentative approval for its abbreviated new drug application for sorafenib tablets (200mg) from the US Food and Drug Administration," Natco said in a statement.Sorafenib is indicated for the treatment of certain types of cancers, including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.Natco and Mylan have filed the abbreviated new drug application containing a paragraph IV certification for this product.The company manufactures this product at its facility in Kothur, Mahaboobnagar district, in Telangana.

OSIMERT 80 MG (OSIMERTINIB) TABLETS

Tefacinix Medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis

Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. Niraparib was granted fast track designation by the US Food and Drug Administration, and Tesaro submitted a new drug application in 2016.

Neratinib is a tyrosine kinase inhibitor anticancer drug.

Eltrombopag treatment should be initiated by and remain under the supervision of a physician who is experienced in the treatment of haematological diseases or the management of chronic hepatitis C and its complications.

Larotrectinib was initially awarded orphan drug status in 2015 for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.[2] Some clinical trial results were announced in 2017.[3] On 26 November 2018, Larotrectinib was approved by the FDA.